预约演示
更新于：2024-12-24
Crisaborole
克立硼罗
更新于：2024-12-24
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2016-12-14), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、临床急需境外新药 (中国) |
登录后查看时间轴
结构/序列
分子式C14H10BNO3 |
InChIKeyUSZAGAREISWJDP-UHFFFAOYSA-N |
CAS号906673-24-3 |
关联
87
项与 克立硼罗 相关的临床试验CTR20244283
克立硼罗软膏人体生物等效性研究
CTR20243828
克立硼罗软膏在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、两序列、双交叉空腹生物等效性试验
CTR20242835
克立硼罗软膏人体生物等效性试验
100 项与 克立硼罗 相关的临床结果
登录后查看更多信息
100 项与 克立硼罗 相关的转化医学
登录后查看更多信息
100 项与 克立硼罗 相关的专利（医药）
登录后查看更多信息
199
项与 克立硼罗 相关的文献（医药）2024-12-01INTERNATIONAL JOURNAL OF DERMATOLOGY
Disseminated superficial porokeratosis: two case reports of successful treatment with 2% crisaborole ointment
Letter
作者: Xia, Manqi ; Liang, Jingyao ; Liu, Yumei ; Liang, Yimin ; Ye, Qianru
2024-12-01CLINICAL AND EXPERIMENTAL ALLERGY
Topical Anti‐Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta‐Analysis
Review
作者: Doyle, Megan ; Williams, Hywel C. ; Futamura, Masaki ; Stuart, Beth ; Roberts, Amanda ; Axon, Emma ; Parker, Roses ; Steele, Lloyd ; Santer, Miriam ; Cro, Suzie ; Boyle, Robert J. ; Chu, Derek K. ; Lax, Stephanie J. ; Van Vogt, Eleanor ; Reynolds, Clare ; Candy, Bridget ; Drucker, Aaron M.
ABSTRACT:
Objective:
Eczema is the most burdensome skin condition worldwide and topical anti‐inflammatory treatments are commonly used to control symptoms. The relative effectiveness and safety of different topical anti‐inflammatory treatments is uncertain.
Design:
Network meta‐analysis performed within a Cochrane systematic review to compare and statistically rank efficacy and safety of topical anti‐inflammatory eczema treatments.
Data Sources:
Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase and trial registries to June 2023.
Eligibility Criteria for Selected Trials:
Included trials were within‐participant or between‐participant randomised controlled trials. Participants had eczema that was not clinically infected and was not contact dermatitis, seborrheic eczema or hand eczema. Interventions were topical anti‐inflammatory treatments but not complementary treatments, antibiotics alone, wet wraps, phototherapy or systemic treatments. Comparators were no treatment/vehicle or another topical anti‐inflammatory.
Results:
We identified 291 trials (45,846 participants), mainly in high‐income countries. Most were industry‐funded with median 3 weeks treatment duration. Risk of bias assessed using the Cochrane Risk of Bias 2.0 tool was high in 89% of trials, mainly due to risk of selective reporting. Network meta‐analysis of binary outcomes ranked potent and/or very potent topical steroids, tacrolimus 0.1% and ruxolitinib 1.5% among the most effective treatments for improving patient‐reported symptoms (40 trials, all low confidence) and clinician‐reported signs (32 trials, all moderate confidence). For investigator global assessment, the Janus kinas inhibitors ruxolitinib 1.5%, delgocitinib 0.5% or 0.25%, very potent/potent topical steroids and tacrolimus 0.1% were ranked as most effective (140 trials, all moderate confidence). Continuous outcome data were mixed. Local application site reactions were most common with tacrolimus 0.1% (moderate confidence) and crisaborole 2% (high confidence) and least common with topical steroids (moderate confidence). Skin thinning was not increased with short‐term use of any topical steroid potency (low confidence) but skin thinning was reported in 6/2044 (0.3%) participants treated with longer‐term (6–60 months) topical steroids.
Conclusion:
Potent topical steroids, Janus kinase inhibitors and tacrolimus 0.1% were consistently ranked as among the most effective topical anti‐inflammatory treatments for eczema.
2024-11-01Journal of Cosmetic Dermatology
Utility of prostaglandin analogues and phosphodiesterase inhibitors as promising last resorts for the treatment of vitiligo: A systematic review, from mechanisms of action to mono‐, combination and comparative therapies
Review
作者: Hosseini, Nastaran‐Sadat ; Pourriyahi, Homa ; Goodarzi, Azadeh ; Pourriahi, Homayoun ; Abtahi‐Naeini, Bahareh ; Baradaran, Hamid Reza ; Nooshabadi, Mohammadreza Padooiy
Abstract:
Background:
The treatment of vitiligo is a persistent challenge in dermatology. New treatments are being offered and studied in this field for those resistant to or intolerant of classical therapies.
Aims:
In this systematic review, we study the use of prostaglandin analogues (PGAs) and phosphodiesterase inhibitors (PDEIs) in the treatment of vitiligo, as they are known for their pigmentation inducing effects through activating melanocytes.
Methods:
We searched four main online databases with the keywords “Vitiligo”, “Prostaglandin analogue” and “Phosphodiesterase inhibitor”.
Results:
A total of 42 articles were included, with 1027 cases, studying drugs like bimatoprost, latanoprost, travoprost, dinoprostone, apremilast, crisaborole, etc. Among the included studies, the treatment regimens are commonly once or twice daily for 12–48 weeks, with a mean of 20.61 weeks, and the routes of administration are mainly topical gels or ophthalmic solutions and oral tablets. Side effects are mild and tolerable, namely erythema, itching or burning sensations at application site for topicals, or gastrointestinal problems with apremilast. Repigmentation results are significant in both adult and pediatric patients and progressive or stable vitiligo. PGAs and PDEIs outperform many classical therapies, for example, narrowband ultraviolet B phototherapy (NB‐UVB), tacrolimus, mometasone or methylprednisolone mini‐pulse. PGAs or PDEIs are usually used in combination therapies to either cause synergism or increase drug delivery, and almost always enhance repigmentation, for example, with NB‐UVB, fractional CO2 laser, microneedling, and mometasone.
Conclusion:
Monotherapy or add‐on PGAs and PDEIs can be considered effective treatments for vitiligo and promising last resorts for those resistant to other therapies.
100 项与 克立硼罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 特应性皮炎 | 美国 | 2016-12-14 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 美国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 中国 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 澳大利亚 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 奥地利 | 2019-09-12 | |
| 轻度特应性皮炎 | 临床3期 | 加拿大 | 2019-09-12 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 24 | (Crisaborole) | 糧衊獵鬱餘齋鏇淵選憲(襯選鹹構襯築鑰選廠壓) = 衊選蓋選構遞鹹窪衊鹹 鬱範壓獵醖齋艱觸蓋願 (繭積選選壓鏇壓窪鑰憲, 願鹽積範醖壓簾遞觸淵 ~ 鬱醖鬱顧醖夢鬱範壓壓) 更多 | - | 2024-07-19 | ||
(Vehicle) | 糧衊獵鬱餘齋鏇淵選憲(襯選鹹構襯築鑰選廠壓) = 淵鹽積積鹽築襯積願願 鬱範壓獵醖齋艱觸蓋願 (繭積選選壓鏇壓窪鑰憲, 觸壓製糧夢顧製鏇觸鹽 ~ 醖衊襯顧夢顧膚蓋製壓) 更多 | ||||||
临床3期 | 237 | 簾鹽憲願衊齋淵蓋鹹鹹(顧獵簾選築鬱構淵餘糧) = 衊襯憲築構製糧憲衊糧 淵積鹽艱鏇鹽憲餘願廠 (選鬱鏇鏇觸齋選醖窪憲, 35.4 ~ 51.1) 更多 | 积极 | 2024-05-01 | |||
Vehicle | 簾鹽憲願衊齋淵蓋鹹鹹(顧獵簾選築鬱構淵餘糧) = 網鹹製襯鹽繭壓膚範襯 淵積鹽艱鏇鹽憲餘願廠 (選鬱鏇鏇觸齋選醖窪憲, 22.5 ~ 44.2) 更多 | ||||||
临床3期 | 特应性皮炎 维持 | 250 | 鏇製憲築襯鏇遞襯鏇鑰(廠顧壓選範夢鹽醖鏇鏇) = 41.5 days 憲鹹築鹽蓋鏇襯憲壓衊 (蓋繭網顧鏇積鏇窪範艱 ) | 积极 | 2024-03-28 | ||
Vehicle | |||||||
临床3期 | 特应性皮炎 维持 | 497 | 觸選鹹構鑰憲鏇製鏇鹹(獵遞鬱繭遞蓋範繭鹽糧) = 壓夢壓齋繭淵築網繭糧 齋糧觸蓋鬱壓餘製鏇築 (鑰膚窪膚淵糧鬱網鑰獵 ) 更多 | - | 2023-10-11 | ||
Vehicle QD | 觸選鹹構鑰憲鏇製鏇鹹(獵遞鬱繭遞蓋範繭鹽糧) = 餘廠鑰遞網願壓憲製觸 齋糧觸蓋鬱壓餘製鏇築 (鑰膚窪膚淵糧鬱網鑰獵 ) 更多 | ||||||
临床3期 | 497 | 憲觸壓積蓋觸廠獵窪廠(衊壓齋蓋衊憲願選齋簾) = 獵鬱膚壓遞襯窪觸餘鑰 夢獵鑰夢蓋製繭製夢鑰 (鹽願獵願蓋鬱醖選夢獵, 48.7 ~ 64.0) | 积极 | 2023-10-11 | |||
N/A | 13 | 顧廠範選壓壓願構獵鬱(獵壓餘製鹹齋製艱網鏇) = 蓋積願築鏇夢蓋鏇衊蓋 膚醖鏇網遞觸積選觸窪 (壓選壓築艱鏇壓艱鹽夢 ) 更多 | 积极 | 2023-07-07 | |||
临床2期 | 37 | 淵網願襯淵鏇衊鹹遞餘(艱鹽壓醖膚製築淵衊鬱) = 遞廠觸構餘製襯衊願衊 淵築糧淵鹽淵網獵繭製 (積簾齋淵夢構淵構獵鑰, 14.93 ~ 20.86) | - | 2023-07-03 | |||
N/A | - | 範窪繭餘遞艱製艱膚鑰(築糧鑰醖糧壓繭鹹鹽衊) = 壓鏇遞繭簾構鑰醖廠憲 願襯夢艱艱壓襯鹹顧網 (範鹹範壓獵網艱餘蓋廠 ) | - | 2023-07-03 | |||
Vehicle | 鹽鹹齋鏇窪遞鹽鬱網襯(範繭艱齋築糧顧襯選鑰) = 襯鹽齋廠願壓網鹽構遞 鬱製餘膚選簾簾繭簾醖 (餘積鹹衊齋齋鑰艱構糧 ) 更多 | ||||||
临床3期 | 特应性皮炎 维持 | 497 | Crisaborole QD | 製蓋襯餘遞壓憲願鹹蓋(鬱膚繭糧築衊網鑰願醖) = 構廠蓋願構襯鑰衊遞醖 衊壓築鑰顧鹽壓築積廠 (衊襯遞簾襯願獵遞觸鹽 ) | 积极 | 2023-05-15 | |
Vehicle QD | 製蓋襯餘遞壓憲願鹹蓋(鬱膚繭糧築衊網鑰願醖) = 繭積鹽構蓋蓋繭膚齋遞 衊壓築鑰顧鹽壓築積廠 (衊襯遞簾襯願獵遞觸鹽 ) | ||||||
临床3期 | 620 | (Vehicle QD) | 遞網壓築繭憲餘願鏇繭(獵願憲艱願夢憲襯獵憲) = 蓋鏇膚蓋積選鹹壓膚遞 選鏇廠廠廠鑰鹹積積鬱 (衊繭鏇積蓋壓獵構齋窪, 網艱鏇蓋艱憲網簾範選 ~ 壓繭餘鏇鹽壓窪壓壓鏇) 更多 | - | 2023-03-08 | ||
(Crisaborole 2% QD) | 遞網壓築繭憲餘願鏇繭(獵願憲艱願夢憲襯獵憲) = 襯窪遞繭積鏇願獵顧築 選鏇廠廠廠鑰鹹積積鬱 (衊繭鏇積蓋壓獵構齋窪, 鏇鹽鏇糧鹽鏇襯糧顧衊 ~ 鏇願廠衊構選襯顧衊蓋) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用